Impact of Ozanimod on Fecal Calprotectin Levels and the Association With Efficacy in Patients With Moderately to Severely Active Ulcerative Colitis: Results From the Phase 3 True North Study

被引：0
|
作者：
Harris, Sarah [1 ]
Maddux, Rachel [1 ]
Li, Yicong [2 ]
Hu, Sarah [1 ]
Wu, Chun [1 ]
Petersen, AnnKatrin [1 ]
机构：
[1] Bristol Myers Squibb, Princeton, NJ USA
[2] Parexel Int, Durham, NC USA
来源：
AMERICAN JOURNAL OF GASTROENTEROLOGY | 2022年 / 117卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
S780
引用
收藏
页码：S556 / S556
页数：1
相关论文
共 50 条
  • [1] Impact of ozanimod on type III collagen turnover biomarkers and the association with ozanimod efficacy in patients with moderately to severely active ulcerative colitis: Results from the phase 3 True North study
    D'Haens, G.
    Maddux, R.
    Wu, C.
    Hu, Y.
    Sands, B. E.
    Mortensen, J. H.
    Zhang, J.
    Petersen, A.
    Harris, S.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I1234 - I1235
  • [2] Ozanimod Reduced Fecal Calprotectin Levels in Patients with Ulcerative Colitis in the Phase 3 True North Study
    Julio, Chebli
    Liliana, Chebli
    Fernando, Lucca
    Carla, Malaguti
    Isaac, Oliveira
    Pedro, Gaburri
    Tarsila, Ribeiro
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2020, 115 : S3 - S3
  • [3] Impact of Ozanimod on Interleukin-17A Levels and the Association With OZA Efficacy in Patients With Moderately to Severely Active Ulcerative Colitis: Data From the Phase 3 True North Study
    Harris, Sarah
    Maddux, Rachel
    Wu, Chun
    Hu, Yanhua
    Petersen, AnnKatrin
    Vermeire, Everine
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (10): : S867 - S867
  • [4] Impact of Ozanimod on C-Reactive Protein Levels and the Association With OZA Efficacy in Patients With Moderately to Severely Active Ulcerative Colitis: Data From the Phase 3 True North Study
    Harris, Sarah
    Maddux, Rachel
    Wu, Chun
    Hu, Yanhua
    Petersen, AnnKatrin
    Rubin, David T.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (10): : S868 - S868
  • [5] THE EFFECT OF OZANIMOD ON CIRCULATING NEUTROPHILS: RESULTS FROM THE TRUE NORTH STUDY OF PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
    Harris, Sarah
    Wu, Chun
    Li, Yicong
    Maddux, Rachel
    Hu, Sarah
    Petersen, AnnKatrin
    GASTROENTEROLOGY, 2022, 162 (07) : S973 - S973
  • [6] Impact of Baseline Disease Duration on Ozanimod Efficacy in Patients With Moderately to Severely Active Ulcerative Colitis: A Post Hoc Analysis of the Phase 3 True North Study
    Lichtenstein, Gary R.
    D'Haens, Geert R.
    Walsh, Alissa
    Glover, Sarah C.
    Lukin, Dana J.
    Cohen, Benjamin L.
    Lawlor, Garrett
    Rosen, Melissa
    Wu, Hsiuanlin
    Osterman, Mark T.
    Jain, Anjali
    Hart, Ailsa
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (10S): : S960 - S961
  • [7] CORTICOSTEROID-FREE REMISSION IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS TREATED WITH OZANIMOD: RESULTS FROM THE MAINTENANCE PHASE OF TRUE NORTH
    Schreiber, Stefan
    Armuzzi, Alessandro
    Dignass, Axel
    Marta, Cecilia
    Petersen, AnnKatrin
    Huang, Vivian
    Sandborn, William J.
    GASTROENTEROLOGY, 2021, 160 (06) : S83 - S83
  • [8] Impact of Ozanimod (OZA) on Circulating Neutrophils: Results from the Phase 3 Japanese True North (J-TN) Study of Patients (Pts) With Moderately to Severely Active Ulcerative Colitis (UC)
    Zhang, J.
    Gilvary, C.
    Schwarz, J.
    Uchikawa, Y.
    Fujimoto, G.
    Zhang, C.
    Harris, S.
    JOURNAL OF CROHNS & COLITIS, 2025, 19 : i1350 - i1350
  • [9] RAPID INDUCTION EFFECTS OF OZANIMOD ON CLINICAL SYMPTOMS AND INFLAMMATORY BIOMARKERS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE INDUCTION PHASE OF TRUE NORTH
    Osterman, Mark T.
    Longman, Randy
    Sninsky, Charles
    Hanauer, Stephen B.
    Feagan, Brian G.
    Chitkara, Denesh
    Hua, Steven Y.
    Petersen, AnnKatrin
    Afzali, Anita
    Ponich, Terry P.
    Siegmund, Britta
    Sandborn, William J.
    GASTROENTEROLOGY, 2021, 160 (06) : S93 - S94
  • [10] COMPARATIVE EFFICACY AND SAFETY OF OZANIMOD AND USTEKINUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
    Dubinsky, Marla C.
    Betts, Keith
    Eren, Devrim
    Tang, Wenxi
    Yin, Lei
    Gupte-Singh, Komal
    GASTROENTEROLOGY, 2022, 162 (07) : S603 - S603
12345